Purpose: Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer. We investigated the association between grade 3 HFS and genetic variations in genes involved in capecitabine metabolism.
Introduction
Capecitabine (Xeloda) is a 5-fluorouracil (5-FU) prodrug widely used in the treatment of breast and colorectal cancer (1) . The conversion takes place through a 3-step enzymatic process: after activation by carboxylesterase 2 (CES2) and cytidine deaminase (CDD), capecitabine is converted to 5-FU by thymidine phosphorylase (TP), which is highly expressed in tumors and liver. One of the main targets of
5-FU is TS (thymidylate synthase). Finally, 5-FU is catabolized by DPD (dihydropyrimidine dehydrogenase; ref. 2).
Capecitabine offers a more selective alternative to 5-FU, as it is converted into the active form specifically in the tumor cell (2) , lowering the adverse effects related to 5-FU (3) . Even so, hand-foot syndrome (HFS) occurs in a large percentage (almost 30%) of capecitabine-treated patients. HFS is a side effect of continuous 5-FU infusion and of other drugs such as doxorubicin, cytarabine, and docetaxel (4) . It is characterized by tenderness, redness, and swelling of palms and soles and often necessitates dose reduction or even treatment interruption (5) .
Pharmacogenetics aims to understand the relationship between genetic variation and adverse drug reaction (ADR) or treatment response. Genetic analysis of genes involved in the metabolism of anticancer drugs is becoming more and more important for elucidating the interpatient pharmacodynamic variability of anticancer drugs.
With regard to capecitabine, some polymorphisms such as three 28-bp repeats in the 5 0 untranslated region (UTR) of the TS gene containing a G>C mutation in the second repeat, a 6-bp deletion in the 3 0 region of the TS gene, and the inactivating mutation IVS14þ1G>A in the DPD gene (6) (7) (8) have been related to severe global toxicity appearance when ADRs such as myelosuppression, hematologic toxicity, diarrhea, and HFS are grouped.
The aim of the present study was to investigate the relationship between capecitabine-induced HFS and polymorphisms in genes of the capecitabine metabolic pathway (CES2, CDD, TP, and DPD) and target gene (TS).
Methods

Study subjects
This retrospective study included 130 patients with a diagnosis of breast cancer or colorectal cancer treated at the Hospital Universitario San Carlos, Madrid, Spain, between June 2005 and March 2009. The study was conducted according to the Declaration of Helsinki and approved by the Ethics Committee of the institution. All patients signed an informed consent. Most (72%) of the patients were diagnosed with breast cancer, whereas the remaining patients had colorectal cancer. The median age at diagnosis was 63 years (range ¼ 28-88 years), and 112 patients (86%) were female.
Capecitabine was administered according to 2 different schedules. Colorectal cancer patients were treated with a standard regimen (1,250 mg/m 2 orally every 12 hours on days 1-14 every 3 weeks), whereas breast cancer patients were treated either with the same standard regimen or with a continuous regimen (800 mg/m 2 orally every 12 hours daily).
HFS was graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (version 2). Grade 3 HFS was defined as skin changes with pain interfering with function. For study purposes, we used as study endpoint the maximum HFS grade experienced by the patients along the treatment, considering grade 0-2 of HFS as no or low toxicity and grade 3 as high toxicity. Other clinical data were recorded such as age, sex, capecitabine regimen, number of reductions, and hepatic metastasis (as a variable that could interfere with capecitabine metabolism; Table 1 ).
Genotyping
A total of 13 polymorphisms located in 5 different genes were analyzed in the 130 breast and colorectal cancer patients. Eleven polymorphisms were located in capecitabine metabolic pathway genes. In the CDD gene, single nucleotide polymorphisms (SNP) rs532545 À451C > T, rs602950 À92A > G, both located in the promoter, and Lys27Gln, the coding SNP rs2072671 (9-13); in the DPD gene, the intronic SNP rs3918290, IVS14þ1G>A, in the splice donor site flanking exon 14 that causes exon skipping and inactivation of DPD allele (7, (14) (15) (16) ; in the CES2 gene, rs2241409, rs11568314, rs11568311, all intronic SNPs, and rs11075646 823C > G; in the CES2 gene promoter and in the TP gene, the intronic SNP rs470119 and the coding SNPs rs11479 Ser471Leu and rs131804 Ala324Ala. The remaining 2 polymorphisms were located in the 5-FU target gene TS, a 28-bp double-or triple-tandem repeat, including a G > C mutation in the 5 0 region and a 6-bp deletion in the 3 0 region (6, 14, 17) .
Translational Relevance
This article shows evidences of a role of a CDD genetic variant in capecitabine-induced severe hand-foot syndrome appearance, suggesting that this variant might be useful to prevent this adverse event in patients treated with this drug. These findings give new insights to elucidate the mechanisms of capecitabine-related toxicity and could help in individualizing the treatment. All polymorphisms have been described in the literature as possible functional variants except in the TP and CES2 genes, for which, because of the lack of candidate functional SNPs, tagSNPs were selected.
Genomic DNA was extracted from peripheral blood lymphocytes by automatic DNA extraction (MagNA Pure; Roche) according to the manufacturer's protocol. DNA was quantified using PicoGreen (Invitrogen Corp.).
Genotypes were determined using the KASPar SNP genotyping system (KBioscience). Allelic discrimination was carried out using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems).
For the polymorphisms in the TS gene, restriction fragment length polymorphisms (RFLP) and direct sequencing were used. In particular for the 5 0 -UTR polymorphism, a fragment containing the 28-bp repeat was amplified starting from 100 ng genomic DNA, using the following primers: 5 0 -TTCCCGGGTTTCCTAAGACT-3 0 and 5 0 -TGGATCTGCCCCAGGTACT-3 0 . PCR products were purified by ExoSap-IT (USB Corporation) and directly sequenced using an ABI3730 DNA analyzer (Applied Biosystems). 3 0 -UTR variation was analyzed by RFLP as described (6) .
Duplicate and negative samples were included in all assays.
Fine mapping at the CDD promotor
A 959-bp fragment of the promoter was amplified from 30 healthy controls, using the following primers: 5 0 -ATG-CAGTGGTGCAATCTGAG-3 0 and 5 0 -GTGCCCACCTT-TACCTTTGA-3 0 . After purification, DNA fragments were sequenced as described earlier.
Lymphoblastoid cell cultures
Eighty-nine lymphoblastoid cell lines derived from the Caucasian Utah CEPH lines were purchased from the Coriell Institute for Medical Research (Camden, NJ). Lymphoblastoid cell lines were cultured in RPMI 1640 containing 15% FBS (Euroclone) and maintained in a humidified incubator at 37 C and 5% CO 2 . Genomic DNA and total RNA were extracted from exponentially growing cells, using DNAZol (MBC; Molecular Research Center, Inc.) and TRIzol (Invitrogen), respectively, according to the manufacturer's protocol. DNA was genotyped for rs532545, rs602950, rs2072671, rs3215400, and rs603412 SNPs by Kaspar Genotyping Assays as described earlier.
Gene expression assay
One microgram of RNA was reverse transcribed using an oligo(dT) 18 primer and Superscript II Reverse Transcriptase (Invitrogen) according to the manufacturer's recommendations. Real-time PCR was carried out in the 89 cell lines by using the TaqMan Gene Expression Assays (Applied Biosystems), following the manufacturer's protocol (Hs00156401_m1 probe for CDD) on an ABI PRISM 7900 Sequence Detection system (Applied Biosystems). The glyceraldehyde 3-phosphate dehydrogenase transcript level was used as a reference (Hs9999905_m1). Data were analyzed using absolute quantification on resulting C t (cycle threshold) values generated on the sequence detection system. Serial dilutions of cDNA of a control sample were used to generate standard curves, and quantity mean (Qty mean) for each sample was calculated. Each sample was evaluated in triplicate.
Prediction of transcription factor binding sites
We carried out in silico prediction of putative transcription factor binding sites by using TFSEARCH (http://www. cbrc.jp/research/db/TFSEARCH.html, v1.3) and Jaspar (http://jaspar.cgb.ki.se/).
Allele-specific expression assay
Allele-specific mRNA expression was measured amplifying a 244-bp region around SNP rs3215400 in the 43 Caucasian lymphoblastoid cell lines heterozygous for this SNP. The following primers were used: 5 0 -AAAGCTGCGTACCTGAGAGC-3 0 and 5 0 -TGACTGTAGG-GGCAGTAGGC-3 0 . cDNA was prepared from RNA treated with DNase I (Ambion), using Superscript II Reverse Transcriptase (Invitrogen) with random hexamers according to the manufacturer's recommendations.
Primer extension with fluorescent dideoxynucleotides was done using the SNaPshot System (Applied Biosystems), followed by capillary electrophoresis on an ABI3730 DNA analyzer (Applied Biosystems). Data were analyzed by Peak Scanner 1.0 software (Applied Biosystems).
Allele-specific expression (ASE) ratios were calculated as follows: the ratio between the 2 alleles' peak area of cDNA was divided by the same ratio for genomic DNA. Each sample was assayed using 2 independent cDNA preparations; 2 independent single base extensions were run for each cDNA preparation, giving a total of 4 replicates. The SNaPshot ASE variation value for each individual is given as the average of the 4 analyses.
Statistical analysis
The main objective of the study was to assess the correlation between SNP variations and severity of HFS (low or grades 0-2, vs. high or grade 3 þ 4). Associations between SNPs and HFS were assessed using logistic regression analysis, comparing genotype frequencies in patients with low toxicity and high toxicity, and estimating ORs. Individuals who were homozygous for the most frequent allele were used as the reference group.
Sex, age (continuous), tumor type (colorectal and breast cancer), capecitabine dose (continuous), and number of dose reductions were included as covariates in multivariate logistic regression.
In addition to the model comparing the genotypes separately (codominant model), we considered log-additive, dominant, and recessive models.
Associations between gene expression and SNPs in cell lines were assessed by ANOVA when considering the 3 genotypes separately and Student's t test, assuming equal variances considering the wild-type homozygous versus the polymorphic heterozygous and homozygous genotypes. All expression data (Qty mean) were log 2 transformed to obtain normally distributed data.
The R (version 2.6.0.2) and the SPSS software (version 13.0, SPSS Inc.) were used for all analyses, and the values of P ! 0.05 were considered statistically significant. We estimated that at a nominal statistical significance level of 0.05, our study had 80% power to detect ORs under a dominant model of at least 3.0 for all but the less frequent SNPs (rs11568314, rs11568311, and rs11479) for which the minimum OR detectable was 6.0.
Results
The polymorphisms analyzed and the genotypic frequencies are shown in Table 2 . The minor allele frequencies (MAF) were between 0.06 and 0.42. There was no evidence of departure from the Hardy-Weinberg equilibrium for any of them. Call rate was more than 99% for all samples, and duplicated samples showed an extremely high concordance (>99%). Grade 3 HFS was observed in 41 (32%) of the 130 patients treated with capecitabine.
We found a significant association with HFS only for a polymorphism in the CDD gene. In particular, the polymorphic T allele of rs532545 was associated with higher incidence of grade 3 HFS: the estimated OR was 2.02 (P ¼ 0.039). No substantial changes were observed in this OR after adjustment for capecitabine dose, tumor type, age, and hepatic metastasis, whereas adjustment for dose reduction increased the significance of the association. No evidence of association was found for the polymorphisms in the other genes considered ( Table 2) .
We found only 1 patient heterozygous for the DPD SNP rs3918290, and this patient experienced life-threatening toxicities (severe myelosupression and mucositis). This SNP was not included in the analyses. Lethal outcome or high toxicity has been reported after treatment with 5-FU or capecitabine (8, 16, 18) .
Because of the SNP associated with HFS is located in the promoter of the CDD gene and had been described to affect transcription by Fitzgerald and colleagues (10), we analyzed the relationship with CDD mRNA levels by quantitative real-time PCR. Because RNAs were not available for our patients, 89 lymphoblastoid cell lines from Caucasian healthy individuals were used for this purpose. After genotyping of rs532545 (MAF ¼ 0.29) in these cell lines, we found that this SNP was not associated with a significant change in mRNA levels (P ¼ 0.671).
Neither of the other 2 SNPs in the CDD gene analyzed (rs602950, MAF ¼ 0.29; rs2072671, MAF ¼ 0.36) was associated with gene expression (P values of 0.655 and 0.327 for rs602950 and rs2072671, respectively).
We hypothesized that rs532545 might not be the causal SNP but simply a marker SNP, so we searched by fine mapping of the promoter for other variants that showed stronger association with HFS. We sequenced a 959-bp fragment at the 5 0 extreme of the CDD gene and found, apart from the 3 SNPs originally included in the study (rs602950, rs532545, and rs2072671), 2 more common variants already annotated in the dbSNP database (rs3215400 and rs603412). We genotyped our series of 130 patients for these 2 variants and found a statistically significant association with HFS for rs3215400 (Table 3 ). In particular, carriers of at least one inserted C allele of rs3215400 had lower risk of developing grade 3 HFS (OR ¼ 0.37, P ¼ 0.020) compared with individuals homozygous for the deleted allele. Further analysis was carried out for this variant, comparing grade 0 versus 3 to better discriminate the HFS phenotype. Although the sample size was greatly reduced (N ¼ 96), the statistical significance was maintained (P ¼ 0.045). This variant is in linkage disequilibrium (LD) with the previously associated rs532545 (D 0 ¼ 0.92), and the LD block structure under the association interval is given in Figure 1A . To see whether the effect we observed was due to a single variant or to a combination of the 2 associated polymorphisms, rs532545 and rs3215400, we also analyzed the effect of the haplotypes on HFS. We found that the haplotypes that conferred an increased risk of developing HFS were only those that contained the deleted allele of the rs3215400 variant (data not shown).
We genotyped by the same approach the 2 polymorphisms we found after promoter sequencing, rs3215400 (MAF ¼ 0.44) and rs603412 (MAF ¼ 0.44), in the 89 lymphoblastoid cell lines. Again, we investigated the correlation with gene expression and found that the rs3215400 variant was associated with a significant difference in CDD mRNA levels. The median expression in cell lines with the homozygous del-del genotype was 3.1-fold higher than that of those with del-C heterozygous and CC homozygous genotypes (P ¼ 0.004; Fig. 1B) . The other CDD variant rs603412 was not significantly associated with gene expression (P ¼ 0.4).
To elucidate whether the associated rs3215400 marker could be a putative functional variant, we carried out an in silico analysis with two different computer tools for the prediction of transcription factor binding sites and we found that the deleted allele of rs3215400 abrogates a binding site for the transcription factor E2F (Fig. 2A) . Because of the global gene expression association and location in a putative transcriptional element, a more comprehensive analysis was carried out. Specifically, we measured ASE by SNaPshot in both genomic DNA and cDNA of the 43 cell lines heterozygous for rs3215400. As expected, the allelic ratio for genomic DNA was around 1, ranging from 0.95 to 1.6; in contrast, all samples analyzed displayed an increased allele ratio in cDNA compared with genomic DNA (Fig. 2B) . In all cell lines analyzed, the ASE ratio for the deleted allele versus the C allele was more than 3, with an average value of 5.7 (range ¼ 3.9-7.7; SD ¼ 0.83). 
Discussion
In the present study, we used a candidate pathway approach that analyzes polymorphisms across the genes responsible for metabolizing capecitabine and found an association between rs3215400 polymorphism in the CDD gene and grade 3 HFS.
The CDD gene encodes an enzyme involved in the pyrimidine salvage pathway and catalyzes irreversibly the hydrolytic deamination of cytidine and deoxycytidine to their corresponding uridine derivatives (10) . In addition, CDD plays an essential role in the metabolism of a number of antitumor cytosine nucleoside analogues, leading to their pharmacologic activation to 5-FU.
To date, several studies have addressed the relationship between polymorphisms in the CDD gene and sensitivity to cytosine nucleoside analogues or related toxicities. The G208A polymorphism has been reported to be associated with 1b-D-arabinofuranosylcytosine sensitivity (19) and gemcitabine-related toxicities in the Japanese population (20) , but it was not included in our study because it is almost monomorphic in the Caucasian population (12, 13) . The 79A>C variant (rs2072671), which we did include in our study, has been reported to be related to gemcitabine sensitivity, but there is no clear evidence of a functional role or association with toxicities (19) . Fitzgerald and colleagues (10) reported a difference in CDD expression considering haplotypes containing rs602950 and rs532545, but because this haplotype is very rare (!1%) in our series of patients and in cell lines, it cannot account for the differences in expression observed. To our knowledge, only Ribelles and colleagues (9) have analyzed the association between the rs3215400 CDD polymorphism and HFS, but not significant correlation was found. Because of the limited sample size in the study of Ribelles and colleagues, their negative result could be a consequence of a lack of statistical power. Although the present study has been conducted using a limited number of patients as well, the further functional study conducted in cell lines supports our finding showing that the association observed in patients probably reflects the effect of this regulatory variant on CDD expression. Of the 5 common variants we analyzed at the CDD locus, rs3215400 found to be the most strongly associated with HFS. We hypothesized, based on in silico analysis, that the presence of a C allele at position 943 of the CDD gene is critical for transcriptional suppression of the CDD gene resulting in reduced CDD production and that such suppression is mediated through E2F binding. Such a functional explanation is in agreement with our observation that the deleted allele is associated with an increase in global CDD gene expression. We also found a consistent degree of ASE, with the deleted allele expressing 3-to 7-fold higher mRNA levels than the inserted allele, a result consistent with the global gene expression analysis. Because the functional experiments were done in lymphoblastoid cell lines show notable differences in the transcriptional activities of the deleted and C alleles, we infer that this could also happen in patients in vivo and therefore that the rs3215400 variant could be the causal variant.
On the basis of our findings, we propose a model in which the absence of an E2F site within the CDD promoter enhances CDD transcription. This could also take place in normal tissues. In particular, cell cytotoxicity could be accentuated by the elevated proliferation rate observed in the skin of the palm and sole, rendering them more sensitive to the cytotoxic effects of the 5-FU (21) . This model may explain the capecitabine-related HFS variability found in treated patients.
Although our finding requires replication through more extensive and independent series of patients, our results provide evidence that rs3215400 in the CDD gene is a risk factor for HFS. An independent series of patients treated with capecitabine enrolled in a clinical trial (Standard Versus Continuous Capecitabine in Advanced Breast Cancer, NCT00418028) is being collected for validation.
This pharmacogenetic study provides new insight into the clinical toxicity associated with capecitabine treatment.
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